Apalutamide was originally developed by Aragon Pharmaceuticals in the United States. It was then taken over by Johnson & Johnson in 2013 and was approved for marketing by the U.S. Food and Drug Administration (FDA) on February 14, 2018. Apalutamide is a second-generation nonsteroidal andro...